GlobeNewswire by notified

Dante Labs highlights advancements to its drug discovery development program, demonstrating the value of genomic data to drug discovery

Share

– Company announces rebranding to Dante Genomics to reflect its broader global efforts –

NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Dante Genomics, a global leader in genomics and precision medicine, highlights significant progress made in its drug discovery development program with six drug candidates currently in the Company’s pipeline, applying Dante’s internal siRNA and mRNA technology to rare and common diseases.

Since the company’s foundation, Dante has invested in a robust R&D program with the goal to create end-to-end solutions from diagnosis to therapy. Dante’s program began with a focus on rare disease, in response to a diagnosis of a patient with a rare disease for which there were no treatment therapies. Dante’s pipeline has evolved across multiple disease areas with four drug programs in full internal development and two in co-development to achieve validation and partner externally on clinical trials and commercialization.

“Personalized medicine needs personalized data, and our progress in the last 18 months alone demonstrates the value of genomic data to research and discovery drug development,” said Andrea Riposati, CEO of Dante Genomics. “When we founded Dante Genomics, we felt we had a responsibility to deliver personalized medicine beyond diagnosis so that no patient would be facing a diagnosis with no effective treatments. It is this holistic approach that challenges and motivates us as a company to accelerate science to save more lives.”

Dante has advanced its internal drug programs in muscle rare disease and neurological rare disease into the pre-clinical phase. The newest addition to Dante’s discovery program pipeline is an mRNA oncology therapeutic in the molecular discovery phase meant to strengthen the immune system against certain cancer types. In co-development with US biotechnology company Protelica, Dante has therapies in respiratory disease and ovarian cancer, both in the non-regulatory pre-clinical phase.

Dante’s mRNA COVID vaccine program development began in early 2021 and has recently completed the regulatory pre-clinical phase and is ready for its first in-human.

“My academic background has taught me the value of RNA therapeutics, and Dante’s internal R&D leverages mRNA and siRNA technology to accelerate time to patients from concept to clinic,” said Mattia Capulli, Chief Scientific Officer of Dante Genomics. “The data and advanced timeline of our mRNA vaccine program demonstrates Dante’s high quality RNA platform and the reproducibility of this model applied to other clinical therapies.

The Company also announced its rebrand to Dante Genomics to better reflect its global efforts in genomic information and personalized medicine. The company name, Dante Genomics, comes from the compound of humanity and science. “Dante” refers to the Italian humanitarian poet and “Genomics” refers to the powerful science that takes place in a genomics lab. Since its foundation, Dante Genomics has delivered hundreds of thousands of people with affordable, quality genomic solutions to inform their healthcare decisions. The Company’s holistic approach to medicine spans from sequencing and variant interpretation to discovery drug development.

About Dante Genomics

Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

Contact:

Laura D’Angelo
VP of Investor Relations
ir@dantelabs.com
+39 0862 191 0671
www.dantegenomics.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5e163117-b6e3-40cc-8ecc-48cd9d72e8ce


To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Cleantech Building Materials: Grant of Options2.7.2022 09:00:00 CEST | Press release

2 July 2022 CLEANTECH BUILDING MATERIALS PLC, NASDAQ FIRST NORTH GROWTH MARKET, COPENHAGEN TICKER: CBM Cleantech Building Materials plc GRANT OF OPTIONS Cleantech Building Materials plc (“CBM” or the “Company”) is advancing on its strategy to build the first Accoya® Wood factory in China (“Project”). As the Project transitions to a build and operate phase, the Company recognises the importance of retaining and rewarding key persons. Accordingly CBM has today granted new options under the Cleantech Building Materials PLC 2021 Unapproved Share Option Scheme to certain members of its senior management team and senior advisors (“Options”) to subscribe for up to an aggregate of 961,028 ordinary shares of £0.10 each in the Company. All of the Options have the same terms which include an exercise price of €0.42, a vesting period under which a third of the Options granted are exercisable from 2 July 2023, and the remaining two thirds are exercisable in two tranches of one third each upon the c

TGS Named Successful Bidder in the Auction Process for ION Assets1.7.2022 20:38:28 CEST | Press release

OSLO, Norway (1 July 2022) – TGS ASA, a global provider of energy data and intelligence, today announced that it has been named a successful bidder in the auction process conducted in connection with ION Geophysical Corporation’s (ION) Chapter 11 bankruptcy case pending in the United States Bankruptcy Court for the Southern District of Texas. As a result, TGS will acquire certain assets related to ION’s multi-client and processing businesses (referred to as the E&P Technology and Services (EPTS) business), including all of ION’s global offshore multi-client data library and ION’s data processing and imaging capabilities and intellectual property. ION’s data library consists of over 637,000 km of 2D and over 317,000 sq km of 3D multi-client seismic data in major offshore petroleum provinces globally. The revenues associated with the acquired assets were in excess of USD 86M in 2021. TGS intends to employ a number of the ION employees associated with the acquired businesses. The transact

Cool Company Ltd. – Formation Completed1.7.2022 18:46:54 CEST | Press release

Golar LNG Limited ("Golar") announces today that it has sold to Cool Company Ltd. (“CoolCo”) the management organization responsible for the technical and commercial management of LNG carriers, and the provision of such services to third parties, as contemplated in the January 2022 Cool Company Ltd. formation update. CoolCo paid the previously agreed purchase price of $5 million in cash for the shares plus $1.5 million in working capital. As part of the transaction, approximately 600 maritime and office-based personnel became CoolCo employees. Today, Richard Tyrrell also assumed his position as CEO of CoolCo, replacing Interim CEO Karl Fredrik Staubo. FORWARD LOOKING STATEMENTS This press release contains forward-looking statements (as defined in Section 21E of the Securities Exchange Act of 1934, as amended) which reflects management’s current expectations, estimates and projections about its operations. All statements, other than statements of historical facts, that address activitie

Cool Company Ltd. - Formation Completed1.7.2022 18:37:43 CEST | Press release

Cool Company Ltd. ("CoolCo" or the "Company") is pleased to announce today that it has acquired from Golar Management (Bermuda) Limited the management organization responsible for the technical and commercial management of its LNG carriers and the provision of such services to third parties, as contemplated in the January 2022 Cool Company Ltd. formation update. CoolCo paid the previously agreed purchase price of $5 million in cash for the shares plus $1.5 million in working capital. As part of the transaction, approximately 600 maritime and office-based personnel become employees of CoolCo. Today, Richard Tyrrell also assumed his position as CEO of CoolCo, replacing interim CEO Karl Fredrik Staubo. Richard Tyrrell commented: “CoolCo is delighted to formally welcome the members of the Golar LNG team that provide first class technical and commercial management services to our owned fleet of eight LNG carriers, in addition to providing such services to 20 third party vessels. The acquisi

U.S. Government Orders Additional Monkeypox Vaccines from Bavarian Nordic1.7.2022 16:00:10 CEST | Press release

Bavarian Nordic to supply an additional 2.5 million doses of JYNNEOS® vaccineDoses will be manufactured using existing bulk vaccine from previous orders from BARDADeliveries starting in the fourth quarter of 2022 with the majority to be delivered in 2023 COPENHAGEN, Denmark, July 1, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has ordered an additional 2.5 million doses of liquid-frozen JYNNEOS®, a non-replicating smallpox vaccine and the only FDA-approved vaccine against monkeypox. Deliveries under this contract will start in the fourth quarter of 2022 and continue through early 2023. This order comes a few weeks after an order from BARDA for the delivery of 500,000 doses of the vaccine in 2022 in response to the current monkeypox outbreak. With a previous order from BARD